Z
Zhixin Haozheng (Shanghai) Pharmaceutical Technology
Pioneering stem cell induction and differentiation for in vitro tissue and organ regeneration
About Zhixin Haozheng (Shanghai) Pharmaceutical Technology
Zhixin Haozheng Regenerative Medicine, founded in 2019, focuses on the induction and differentiation of stem cells in vitro, aiming to regenerate tissues and organs. Led by Dr. Cheng Xin, a prominent researcher from the Center for Excellence in Molecular Cell Science, the company has developed a new human endoderm stem cell line with independent intellectual property rights. This line supports large-scale production of artificial islets and livers in vitro. The company operates in the regenerative medicine market, serving clients in the pharmaceutical and healthcare sectors. Its business model revolves around research and development, production, and clinical applications of cell-based therapies. Revenue is generated through the development and commercialization of stem cell-based products and therapies. The team comprises overseas returnees, foreign company executives, and professionals in cell drug applications, ensuring a comprehensive approach to innovation and application.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Drug Development, Stem Cells, Regenerative Medicine, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2025 | $28M | $110M | Shanghai STVC Group | ↗ |
| SEED✓Equity / VC | Sep 2024 | — | — | Zhangjiagang Jintai Jinhong Investment · LEO Group · Pan-Lin Asset Management | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhixin Haozheng (Shanghai) Pharmaceutical Technology in its local ecosystem
The Zhixin Haozheng (Shanghai) Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- ZIZhangjiagang Jintai Jinhong Investment
LEO Group
Pan-Lin Asset Management
Series A1 investor entered at this stage
- SGShanghai STVC Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhixin Haozheng (Shanghai) Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhixin Haozheng (Shanghai) Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








